{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116327","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.394148+00:00","generated_at":"2026-05-30T02:36:05.870096+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Armata completes enrollment of Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia; topline Q1 2025","bullets":["Full enrollment (n=50) achieved for intravenous AP-SA02 in Phase 1b/2a diSArm study targeting Staphylococcus aureus bacteremia.","Topline data expected in Q1 2025; if positive, may support initiation of a pivotal efficacy trial later in 2025.","Dose escalated to 5E10 PFU every 6 hours (2E11 PFU/24h) for 5 days without clinically significant adverse events.","Two blinded subsets observed: one showing evidence of in vivo phage amplification with detectable phage in blood.","Study supported by $21.6M in funding from Defense Health Agency and Joint Warfighter Medical Research Program via MTEC and NMRC-NAMD."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116327","json":"https://secwatch.observer/filing/0001104659-24-116327.json","markdown":"https://secwatch.observer/filing/0001104659-24-116327.md","text":"https://secwatch.observer/filing/0001104659-24-116327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/0001104659-24-116327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/tm2428148d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:36:05.870096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}